Oncology represents 23% of global R&D investment and 41% of all clinical trials in 2024. But only around 5% of drugs entering Phase gain approval. Lack of efficacy accounts for 40–60% of late-stage failures, many of which can be traced back to target selection.

This ebook explores how leading R&D teams are strengthening target identification with a more complete and traceable evidence base, reducing risk, and advancing programs with greater confidence.

Inside the ebook

• Why 40–60% of oncology drug failures trace back to target selection decisions
• The evidence areas required to support a target, and why most evaluations assess only a subset of them
• Real-world examples of teams reducing candidate lists from thousands to hundreds in hours, surfacing targets that manual review would miss.

Teams that build target strategies on complete, transparent, and reproducible evidence are better positioned to make confident decisions, reduce costly failures, and advance promising programs.

Download the eBook.